BEAM had a nice bullish breakout in today's pre-market session, consolidating in the intraday and show signals of a continuation to retest that $22.74 and push on up into the next range with previous resistance being $28.48.
This comes after announcing FDA Regenerative Medical Status for BEAM-101 to treat Sickle Cell Disease 2 weeks ago.
This comes after announcing FDA Regenerative Medical Status for BEAM-101 to treat Sickle Cell Disease 2 weeks ago.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.